Segment Reporting (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
|
Mar. 31, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
segment
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Segment Reporting | |||||||||
| Number of operating segments | segment | 1 | ||||||||
| Number of reportable segments | segment | 1 | ||||||||
| Less: | |||||||||
| General and administrative expenses | $ 2,253 | $ 2,602 | $ 7,591 | $ 8,088 | |||||
| Equity-based compensation | 348 | 522 | 997 | 1,729 | |||||
| Net loss | (4,145) | $ (3,932) | $ (4,570) | (4,930) | $ (6,734) | $ (8,480) | (12,647) | (20,144) | $ (23,487) |
| Life science segment | |||||||||
| Segment Reporting | |||||||||
| Grant income | 2,966 | 1,215 | 10,463 | 13,407 | |||||
| Less: | |||||||||
| Clinical programs | 2,585 | 1,435 | 8,823 | 16,486 | |||||
| Research and development personnel costs | 1,691 | 1,248 | 5,043 | 6,221 | |||||
| Preclinical programs | 396 | 37 | 1,078 | 262 | |||||
| Manufacturing | 287 | 751 | 870 | 1,901 | |||||
| Other research and development expenses | 30 | (5) | 122 | 222 | |||||
| General and administrative expenses | 2,040 | 2,387 | 6,999 | 7,307 | |||||
| Equity-based compensation | 348 | 522 | 997 | 1,729 | |||||
| Other segment items | (266) | (230) | (822) | (577) | |||||
| Net loss | $ (4,145) | $ (4,930) | $ (12,647) | $ (20,144) | |||||
| Other segment reporting description | Other segment items include, other income, net, and interest expense | ||||||||
| X | ||||||||||
- Definition Amount of expense for research and development incurred on clinical programs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development incurred on manufacturing. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development incurred on personnel. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development incurred on preclinical programs. No definition available.
|
| X | ||||||||||
- Definition n/a No definition available.
|
| X | ||||||||||
- Definition Amount of income related to grants specific to company life science segment. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|